Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 9/20 | 0.40 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.40 |
| ▸ | LNPEP | Q9UIQ6 | 6/20 | 0.40 |
| ▸ | NPY4R | P50391 | 6/20 | 0.39 |
| ▸ | NPY1R | P25929 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 3/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19445734 | 1.00 | ERAP2 (0.40) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL17949774 | 0.98 | ERAP2 (0.38) | ERAP2ERAP1LNPEPNPY4RNPY1R | |
| SCHEMBL10260958 | 0.91 | PARP1 (0.40) | NPY4RNPY1RNPY2RNPY5RMMP2 | |
| SCHEMBL10262675 | 0.91 | NPY4R (0.42) | NPY4RNPY1RKMT2ANPY2RNPY5R | |
| SCHEMBL12444369 | 0.91 | NPY4R (0.42) | NPY4RNPY1RKMT2ANPY2RNPY5R | |
| SCHEMBL16285905 | 0.91 | NPY4R (0.42) | NPY4RNPY1RKMT2ANPY2RNPY5R | |
| SCHEMBL15138938 | 0.91 | NPY4R (0.42) | NPY4RNPY1RKMT2ANPY2RNPY5R | |
| SCHEMBL10261272 | 0.90 | F3 (0.40) | NPY4RNPY1RMMP2HDAC1HDAC6 | |
| SCHEMBL19945118 | 0.89 | NPY4R (0.43) | ERAP2LNPEPNPY4RNPY1RKMT2A | |
| SCHEMBL10261740 | 0.89 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603294-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10206894-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | POLYMEDIX, INC. | 2018-03-08 | — | — | US | disclosed |
| US-9795575-B2 | Compounds for use in treatment of mucositis | INNOVATION PHARMACEUTICALS INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | INNOVATION PHARMACEUTICALS INC. | 2017-08-10 | — | — | US | disclosed |
| US-9457027-B2 | Compounds for use in treatment of mucostis | CELLCEUTIX CORPORATION (US) | 2016-10-04 | — | — | US | disclosed |
| US-9155738-B2 | Compounds for use in treatment of mucostitis | CELLCEUTIX CORPORATION (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | INNOVATION PHARMACEUTICALS INC. | 2014-12-11 | — | — | US | disclosed |
| US-8802683-B2 | Compounds for use in treatment of mucositis | CELLCEUTIX CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | POLYMEDIX, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224640-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885ERAP1 1190/4885LNPEP 1252/4885 |
| US-10603294-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885ERAP1 1190/4885LNPEP 1252/4885 |
| US-20140364364-A1 | COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | MUC1, FUT6, MMP8 | ERAP2 646/4885ERAP1 1190/4885LNPEP 1252/4885 |
| US-20120295922-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885ERAP1 1190/4885LNPEP 1252/4885 |
| US-10206894-B2 | Compounds for use in treatment of mucositis | MUC1, FUT6, SI | ERAP2 692/4885ERAP1 1246/4885LNPEP 802/4885 |
| US-20190282521-A1 | Compounds For Use In Treatment Of Mucositis | MUC1, FUT6, MMP8 | ERAP2 646/4885ERAP1 1190/4885LNPEP 1252/4885 |
| US-20180064664-A1 | Compounds For Use In Treatment of Mucositis | MUC1, FUT6, SI | ERAP2 692/4885ERAP1 1246/4885LNPEP 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.